Kala Accounts Payable vs Total Stockholder Equity Analysis

KALA Stock

USD 6.91 0.11 1.62%

Kala Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kala Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kala Pharmaceuticals is a good investment. Please check the relationship between Kala Pharmaceuticals Accounts Payable and its Total Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Accounts Payable vs Total Stockholder Equity

Accounts Payable vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kala Pharmaceuticals Accounts Payable account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.

The correlation between Kala Pharmaceuticals' Accounts Payable and Total Stockholder Equity is 0.65. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Kala Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kala Pharmaceuticals' Accounts Payable and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Kala Pharmaceuticals are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Accounts Payable i.e., Kala Pharmaceuticals' Accounts Payable and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.65

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Kala Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Kala Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from Kala Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kala Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.At present, Kala Pharmaceuticals' Sales General And Administrative To Revenue is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 29.6 M, whereas Selling General Administrative is forecasted to decline to about 20.7 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.3M	860K	303K	287.9K
Interest Income	104K	664K	2.5M	2.6M

Depreciation And Amortization Interest Income

Kala Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments
Total Assets		0.76	0.88	0.74	0.87	-0.42	0.8	0.86	0.78	0.87	0.61	-0.13	0.37	0.71	-0.06	0.96	-0.32	0.83	0.71	0.9	0.71	0.84	-0.29	0.87	0.83	0.94
Total Current Liabilities	0.76		0.61	0.73	0.59	-0.63	0.66	0.65	0.52	0.85	0.91	0.03	0.78	0.66	0.19	0.75	-0.23	0.8	0.43	0.77	0.97	0.47	-0.13	0.56	0.68	0.66
Total Stockholder Equity	0.88	0.61		0.6	1.0	-0.43	0.65	0.85	0.62	0.7	0.37	0.0	0.33	0.38	0.21	0.9	-0.04	0.67	0.55	0.75	0.51	0.68	-0.43	0.68	0.64	0.91
Other Liab	0.74	0.73	0.6		0.63	-0.81	0.66	0.65	0.59	0.95	0.64	0.46	0.59	0.73	-0.03	0.76	-0.64	0.6	0.57	0.92	0.74	0.67	0.06	0.7	0.69	0.71
Net Tangible Assets	0.87	0.59	1.0	0.63		-0.48	0.63	0.85	0.6	0.71	0.35	0.07	0.33	0.38	0.22	0.9	-0.08	0.65	0.53	0.75	0.5	0.66	-0.43	0.66	0.62	0.91
Retained Earnings	-0.42	-0.63	-0.43	-0.81	-0.48		-0.3	-0.45	-0.26	-0.67	-0.48	-0.74	-0.77	-0.49	-0.24	-0.54	0.43	-0.31	-0.05	-0.58	-0.58	-0.16	0.04	-0.21	-0.27	-0.5
Accounts Payable	0.8	0.66	0.65	0.66	0.63	-0.3		0.83	0.37	0.75	0.44	-0.19	0.38	0.65	-0.4	0.76	-0.45	0.56	0.77	0.75	0.59	0.68	-0.42	0.68	0.87	0.74
Cash	0.86	0.65	0.85	0.65	0.85	-0.45	0.83		0.38	0.74	0.37	-0.05	0.36	0.62	-0.15	0.92	-0.35	0.59	0.64	0.76	0.56	0.61	-0.66	0.61	0.73	0.94
Other Assets	0.78	0.52	0.62	0.59	0.6	-0.26	0.37	0.38		0.69	0.58	-0.07	0.19	0.55	0.06	0.68	-0.2	0.78	0.46	0.75	0.56	0.79	0.27	0.84	0.59	0.64
Long Term Debt	0.87	0.85	0.7	0.95	0.71	-0.67	0.75	0.74	0.69		0.78	0.21	0.56	0.79	-0.02	0.87	-0.55	0.81	0.66	0.98	0.87	0.76	-0.02	0.81	0.82	0.81
Net Receivables	0.61	0.91	0.37	0.64	0.35	-0.48	0.44	0.37	0.58	0.78		0.0	0.62	0.62	0.23	0.55	-0.24	0.81	0.38	0.7	0.96	0.46	0.22	0.57	0.57	0.43
Common Stock Shares Outstanding	-0.13	0.03	0.0	0.46	0.07	-0.74	-0.19	-0.05	-0.07	0.21	0.0		0.39	-0.03	0.3	0.01	-0.28	-0.15	-0.27	0.15	0.06	-0.18	0.26	-0.17	-0.13	0.0
Other Current Assets	0.37	0.78	0.33	0.59	0.33	-0.77	0.38	0.36	0.19	0.56	0.62	0.39		0.39	0.23	0.45	-0.06	0.34	-0.02	0.44	0.68	0.04	-0.06	0.11	0.29	0.37
Total Liab	0.71	0.66	0.38	0.73	0.38	-0.49	0.65	0.62	0.55	0.79	0.62	-0.03	0.39		-0.45	0.72	-0.75	0.58	0.54	0.76	0.67	0.61	-0.1	0.65	0.63	0.69
Short Long Term Debt	-0.06	0.19	0.21	-0.03	0.22	-0.24	-0.4	-0.15	0.06	-0.02	0.23	0.3	0.23	-0.45		-0.05	0.58	0.16	-0.28	-0.06	0.18	-0.18	0.17	-0.13	-0.28	-0.1
Total Current Assets	0.96	0.75	0.9	0.76	0.9	-0.54	0.76	0.92	0.68	0.87	0.55	0.01	0.45	0.72	-0.05		-0.34	0.77	0.6	0.88	0.69	0.73	-0.4	0.75	0.77	0.99
Short Term Debt	-0.32	-0.23	-0.04	-0.64	-0.08	0.43	-0.45	-0.35	-0.2	-0.55	-0.24	-0.28	-0.06	-0.75	0.58	-0.34		-0.2	-0.42	-0.52	-0.31	-0.39	-0.05	-0.39	-0.45	-0.35
Common Stock	0.83	0.8	0.67	0.6	0.65	-0.31	0.56	0.59	0.78	0.81	0.81	-0.15	0.34	0.58	0.16	0.77	-0.2		0.5	0.78	0.86	0.65	-0.02	0.74	0.81	0.7
Property Plant Equipment	0.71	0.43	0.55	0.57	0.53	-0.05	0.77	0.64	0.46	0.66	0.38	-0.27	-0.02	0.54	-0.28	0.6	-0.42	0.5		0.76	0.44	0.9	-0.11	0.87	0.69	0.58
Short Long Term Debt Total	0.9	0.77	0.75	0.92	0.75	-0.58	0.75	0.76	0.75	0.98	0.7	0.15	0.44	0.76	-0.06	0.88	-0.52	0.78	0.76		0.78	0.86	-0.01	0.89	0.81	0.84
Other Current Liab	0.71	0.97	0.51	0.74	0.5	-0.58	0.59	0.56	0.56	0.87	0.96	0.06	0.68	0.67	0.18	0.69	-0.31	0.86	0.44	0.78		0.49	0.02	0.59	0.71	0.58
Property Plant And Equipment Net	0.84	0.47	0.68	0.67	0.66	-0.16	0.68	0.61	0.79	0.76	0.46	-0.18	0.04	0.61	-0.18	0.73	-0.39	0.65	0.9	0.86	0.49		0.05	0.99	0.71	0.71
Net Debt	-0.29	-0.13	-0.43	0.06	-0.43	0.04	-0.42	-0.66	0.27	-0.02	0.22	0.26	-0.06	-0.1	0.17	-0.4	-0.05	-0.02	-0.11	-0.01	0.02	0.05		0.09	-0.19	-0.47
Non Current Assets Total	0.87	0.56	0.68	0.7	0.66	-0.21	0.68	0.61	0.84	0.81	0.57	-0.17	0.11	0.65	-0.13	0.75	-0.39	0.74	0.87	0.89	0.59	0.99	0.09		0.75	0.72
Non Currrent Assets Other	0.83	0.68	0.64	0.69	0.62	-0.27	0.87	0.73	0.59	0.82	0.57	-0.13	0.29	0.63	-0.28	0.77	-0.45	0.81	0.69	0.81	0.71	0.71	-0.19	0.75		0.73
Cash And Short Term Investments	0.94	0.66	0.91	0.71	0.91	-0.5	0.74	0.94	0.64	0.81	0.43	0.0	0.37	0.69	-0.1	0.99	-0.35	0.7	0.58	0.84	0.58	0.71	-0.47	0.72	0.73

Click cells to compare fundamentals

Kala Pharmaceuticals Account Relationship Matchups

Kala Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	154.3M	221.6M	139.4M	86.8M	55.9M	53.2M
Total Current Liabilities	24.8M	22.2M	37.4M	25.7M	8.3M	7.9M
Total Stockholder Equity	29.7M	100.0M	16.8M	19.0M	7.5M	7.1M
Net Tangible Assets	29.7M	100.0M	16.8M	19.0M	21.8M	21.4M
Retained Earnings	(295.5M)	(399.8M)	(542.4M)	(587.2M)	(629.4M)	(597.9M)
Accounts Payable	2.5M	1.7M	2.8M	2.3M	919K	873.1K
Cash	85.4M	77.3M	92.1M	70.5M	50.9M	79.6M
Other Assets	16.4M	47.1M	11.0M	462K	531.3K	504.7K
Long Term Debt	71.2M	72.2M	78.9M	37.9M	34.2M	43.8M
Net Receivables	13.1M	9.9M	17.5M	6.5M	236K	224.2K
Common Stock Shares Outstanding	684.2K	1.0M	1.3M	1.5M	2.4M	2.6M
Other Current Assets	1.6M	2.8M	6.1M	9.0M	1.7M	2.5M
Total Liab	124.6M	121.6M	122.6M	67.8M	48.4M	91.9M
Total Current Assets	105.5M	171.4M	124.4M	85.9M	52.9M	98.6M
Short Term Debt	1.3M	3.1M	1.4M	5.0M	668K	634.6K
Common Stock	36K	59K	66K	2K	3K	2.9K
Property Plant Equipment	32.5M	9.4M	4.0M	416K	478.4K	454.5K
Short Long Term Debt Total	101.2M	100.9M	80.2M	43.0M	36.3M	61.0M
Other Current Liab	20.9M	17.4M	33.2M	14.1M	5.7M	5.4M
Property Plant And Equipment Net	32.5M	31.0M	4.0M	416K	2.8M	2.6M
Net Debt	15.7M	23.7M	(11.9M)	(27.5M)	(14.6M)	(15.3M)
Non Current Assets Total	48.8M	50.2M	15.1M	878K	3.1M	2.9M
Non Currrent Assets Other	3.8M	6.2M	9.6M	462K	301K	286.0K
Cash And Short Term Investments	85.4M	153.5M	92.1M	70.5M	50.9M	96.5M
Common Stock Total Equity	25K	34K	36K	59K	67.9K	71.2K
Long Term Debt Total	12.0M	70.2M	71.2M	72.2M	83.1M	44.5M
Liabilities And Stockholders Equity	154.3M	221.6M	139.4M	86.8M	55.9M	53.2M
Non Current Liabilities Total	99.9M	99.4M	85.2M	42.2M	40.1M	59.2M
Capital Surpluse	224.0M	306.1M	325.1M	499.7M	574.7M	603.4M
Other Stockholder Equity	325.1M	499.7M	559.1M	606.2M	636.9M	373.2M
Property Plant And Equipment Gross	32.5M	31.0M	6.9M	1.6M	3.9M	3.7M
Accumulated Other Comprehensive Income	(1.5M)	(1.8M)	(2.5M)	4K	4.6K	4.8K
Inventory	4.6M	5.2M	8.6M	7.7M	8.8M	5.6M
Net Invested Capital	100.9M	172.2M	95.7M	61.9M	41.7M	39.6M
Net Working Capital	80.7M	149.2M	86.9M	60.3M	44.5M	78.0M
Capital Lease Obligations	30M	28.7M	1.3M	13K	2.1M	2.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:

How To Invest In Kala

Details

Is Kala Stock a good investment?

Details

What is Kala Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.67)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.40)

Return On Equity

(2.48)

The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kala Accounts Payable vs Total Stockholder Equity Analysis

Accounts Payable vs Total Stockholder Equity

Accounts Payable vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Stockholder Equity

Kala Pharmaceuticals fundamental ratios Correlations

Kala Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kala Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Current Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Short Long Term Debt Total	+ 0.98	Long Term Debt
Other Current Liab	+ 0.97	Total Current Liabilities
Total Current Assets	+ 0.96	Total Assets

Retained Earnings	- 0.81	Other Liab
Other Current Assets	- 0.77	Retained Earnings
Short Term Debt	- 0.75	Total Liab
Common Stock Shares Outstanding	- 0.74	Retained Earnings
Long Term Debt	- 0.67	Retained Earnings
Net Debt	- 0.66	Cash